Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2023-09-01 Declaration of Voting R…
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (the news service of the London Stock Exchange) on September 1, 2023. The content explicitly states the 'Total Voting Rights and Capital' as of August 31, 2023, referencing the FCA's Disclosure Guidance and Transparency Rules. This type of mandatory disclosure regarding the total number of shares with voting rights, often used as a denominator for shareholder notifications, is a standard regulatory announcement. Since it is a short, specific regulatory update that doesn't fit the detailed definitions of 10-K, IR, or ER, and it is clearly an announcement rather than a comprehensive report, it best fits the general 'Regulatory Filings' category (RNS) or potentially a specific capital/share change notification. However, given the context of mandatory disclosure of total voting rights under FCA rules, RNS is the most appropriate general regulatory filing code, as it is a standard market notice. Reviewing the definitions, 'SHA' (Share Issue/Capital Change) might seem relevant, but this is specifically a notification of the *total* outstanding shares for voting purposes, not an announcement of a new issue or capital change event itself. Therefore, RNS (Regulatory Filings) is the best fit for this routine regulatory update.
2023-09-01 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is a notification released via RNS (London Stock Exchange news service) concerning a 'conditional award under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP") to Riad Mishlawi, a Person Discharging Managerial Responsibility ("PDMR")'. This type of filing, detailing transactions or awards involving directors/executives (PDMRs) and their personal holdings/incentives, falls under insider trading or director's dealing disclosures, often mandated by regulations like MAR Article 19. The specific content relates to an executive receiving an award, which is a form of insider transaction disclosure. This aligns most closely with the 'Director's Dealing' category (DIRS), which covers personal share transactions by directors and executives. Although it mentions remuneration, it is specifically about an incentive award grant, not the general remuneration report (DEF 14A). Since it is a specific regulatory disclosure about an executive's transaction/award, DIRS is the best fit.
2023-08-31 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' and details the acquisition and subsequent sale of shares by an executive (Susan Ringdal) under an incentive plan. This type of filing, reporting insider transactions by PDMRs, is specifically covered by the 'Director's Dealing' definition. The presence of 'RNS Number' and the footer referencing the London Stock Exchange and FCA confirms it is a regulatory disclosure, but the specific content points directly to DIRS, not the general RNS fallback.
2023-08-11 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number : 9923I' header and contains the phrase 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details specific share disposals (transactions) by individuals named Bassam Kanaan and Brian Hoffmann, who are identified as PDMRs (Persons Discharging Managerial Responsibilities). This content directly corresponds to the definition of Director's Dealing (insider trades). The presence of the RNS boilerplate confirms it is a regulatory announcement, but the specific content points overwhelmingly to DIRS.
2023-08-10 English
Hikma appoints new President of Injectables
Board/Management Information Classification · 98% confidence The document begins with 'RNS Number : 7127I' and is dated '09 August 2023'. The content announces a specific management change: 'Hikma appoints new President of Injectables business'. This directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management appointment, making MANG the most specific classification. The document length is moderate (5156 chars), suggesting it is the primary announcement, not just a placeholder for a report.
2023-08-09 English
Half-year Report
Earnings Release Classification · 100% confidence The document is an official announcement of interim financial results for the six months ended 30 June 2023. It contains key financial highlights, segment performance, strategic updates, and full-year outlook guidance. While it provides substantive financial data and analysis, it is structured as an initial earnings release (ER) rather than a full interim report (IR). It follows the standard format for a corporate earnings press release, including contact information for investor relations and details on upcoming conference calls. H1 2023
2023-08-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.